In a small cohort of patients with Cushing’s disease, most had their urinary free cortisol normalized after being ...

Therefore, the cross-sectional study evaluated 73 children (ages 1–12) with steroid-sensitive nephrotic syndrome who were in ...

Vertex Pharma to buy Crinetics Pharmaceuticals for $10 billion: Boston Wednesday, July 8, 2026, 14:00 Hrs [IST] Vertex Pharmaceuticals Incorporated, a global biotechnology company ...

Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click for more on VRTZX and CRNX stock.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of ...

Recent advancements have changed the treatment paradigm in congenital adrenal hyperplasia. Treatment options for CAH differ for children vs. adults as treatment goals shift. In the past few years, ...

Vertex to acquire CRNX for $10B, adding approved rare disease drug Palsonify and late-stage pipeline assets to expand its endocrinology portfolio.

Detailed price information for Crinetics Pharmaceuticals Inc (CRNX-Q) from The Globe and Mail including charting and trades.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under 4 ...

Adults whose blood pressure stays dangerously high despite taking three or more medications now have a new option. The FDA ...

Detailed price information for Crinetics Pharmaceuticals Inc (CRNX-Q) from The Globe and Mail including charting and trades.

Previous research primarily evaluated glucocorticoid-induced adrenal insufficiency (GIAI) within a short 4 to 6-week window post-treatment. To address the clinical gap regarding prolonged hormonal ...